Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
R3R01 in Alport Syndrome and Steroid-Resistant FSGS
NCT05267262Phase 2Completed
- Sponsor
- River 3 Renal Corp
- Start
- Jun 2022
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 2, open-label trial of R3R01 in Alport syndrome and focal segmental glomerulosclerosis (FSGS) (3 cohorts), sponsored by River 3 Renal Corp. Primary endpoints: Adverse Events at 12 weeks and Urine Protein-to-Creatinine Ratio at 12 weeks. Started Jun 2022; status: completed.
02
Drugs
R3R01
03
Conditions
Alport syndromefocal segmental glomerulosclerosis (FSGS)
Beyond the preview
Go deeper on NCT05267262.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05267262.